HL156A

HL156A
Clinical data
Other namesIM156, UNII-4G3BUV6ZSK
Identifiers
IUPAC name
  • N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC13H16F3N5O
Molar mass315.300 g·mol−1
3D model (JSmol)
SMILES
  • C1CCN(C1)C(=NC(=NC2=CC=C(C=C2)OC(F)(F)F)N)N
InChI
  • InChI=1S/C13H16F3N5O/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21/h3-6H,1-2,7-8H2,(H4,17,18,19,20)
  • Key:NGFUHJWVBKTNOE-UHFFFAOYSA-N

HL156A is a derivative of metformin and a potent OXPHOS inhibitor and AMPK activating biguanide.[1][2] Certain types of cancer cells requires OXPHOS to survive. By targeting it, HL156A might help in improving anticancer therapy.[3] It is more potent than AICAR or metformin at activating AMPK.[2] It is synthesized by Hanall Biopharma.[4]

Medical uses

It is in phase 1 trial in patients with advanced solid tumor and lymphoma.[5][1]

Pharmacology

Apart from AMPK activation, it also inhibits expression and activation of IGF-1, AKT, mTOR, and ERK.[6][7]

Research

It is researched in multiple conditions like liver and renal fibrosis,[2][8] cancer[6][9] and drug resistance in cancer.[7] A drug HL176OUT04 with similar pharmacology has been also developed.[10]

See also

References

  1. 1 2 Rha, Sun Young; Beom, Seung-Hoon; Shin, Young Geun; Yim, Dong-Seok; Moon, Yong Wha; Kim, Tae Won; Kim, Sun Young; Kim, Gun Min; Kim, Hyo Song; Cheong, Jae-Ho; Lee, Young Woo; Geiger, Barbara Jean; Yoo, Sanghee; Rudoltz, Marc S.; Janku, Filip (2020). "Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors". Journal of Clinical Oncology. 38 (15_suppl): 3590. doi:10.1200/JCO.2020.38.15_suppl.3590. ISSN 0732-183X. S2CID 219780562.
  2. 1 2 3 Tsogbadrakh B, Ju KD, Lee J, Han M, Koh J, Yu Y, Lee H, Yu KS, Oh YK, Kim HJ, Ahn C, Oh KH (2018). "HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model". PLOS One. 13 (8): e0201692. Bibcode:2018PLoSO..1301692T. doi:10.1371/journal.pone.0201692. PMC 6116936. PMID 30161162.
  3. ↑ Xu, Yibin; Xue, Ding; Bankhead, Armand; Neamati, Nouri (2020). "Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?". Journal of Medicinal Chemistry. 63 (23): 14276–14307. doi:10.1021/acs.jmedchem.0c01013. ISSN 0022-2623. PMID 33103432. S2CID 225072329.
  4. ↑ Ju, Kyung Don; Kim, Hyo Jin; Tsogbadrakh, Bodokhsuren; Lee, Jinho; Ryu, Hyunjin; Cho, Eun Jin; Hwang, Young-Hwan; Kim, Kiwon; Yang, Jaeseok; Ahn, Curie; Oh, Kook-Hwan (2016). "HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis". American Journal of Physiology. Renal Physiology. 310 (5): F342–F350. doi:10.1152/ajprenal.00204.2015. PMID 26661649.
  5. ↑ "A Multi Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients with Advanced Solid Tumors and Lymphoma". 15 October 2020. {{cite journal}}: Cite journal requires |journal= (help)
  6. 1 2 Lam TG, Jeong YS, Kim SA, Ahn SG (March 2018). "New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathways". Cancer Science. 109 (3): 699–709. doi:10.1111/cas.13482. PMC 5834796. PMID 29285837.
  7. 1 2 Jeong YS, Lam TG, Jeong S, Ahn SG (August 2020). "Metformin Derivative HL156A Reverses Multidrug Resistance by Inhibiting HOXC6/ERK1/2 Signaling in Multidrug-Resistant Human Cancer Cells". Pharmaceuticals (Basel, Switzerland). 13 (9): 218. doi:10.3390/ph13090218. PMC 7560051. PMID 32872293.
  8. ↑ Lee HS, Shin HS, Choi J, Bae SJ, Wee HJ, Son T, Seo JH, Park JH, Kim SW, Kim KW (October 2016). "AMP-activated protein kinase activator, HL156A reduces thioacetamide-induced liver fibrosis in mice and inhibits the activation of cultured hepatic stellate cells and macrophages". International Journal of Oncology. 49 (4): 1407–14. doi:10.3892/ijo.2016.3627. PMID 27498767.
  9. ↑ Choi J, Lee JH, Koh I, Shim JK, Park J, Jeon JY, Yun M, Kim SH, Yook JI, Kim EH, Chang JH, Kim SH, Huh YM, Lee SJ, Pollak M, Kim P, Kang SG, Cheong JH (October 2016). "Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A)". Oncotarget. 7 (40): 65643–65659. doi:10.18632/oncotarget.11595. PMC 5323181. PMID 27582539.
  10. ↑ The AMPK activators, HL156A and HL176OUT04 reduce thioacetamide-induced hepatic fibrosis via the inhibition of hepatic stellate cell activation (Thesis). 서울대학교 융합과학기술대학원. 2016. hdl:10371/133411.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.